- The European Commission (EC) has granted marketing authorization to PTC Therapeutics Inc's PTCT Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in patients two months and older.
- Evrysdi will be for SMA Type 1, Type 2, or Type 3 patients with one to four SMN2 copies.
- The EC approval is based on two studies - Efficacy results from the FIREFISH study in infants aged 2 to 7 months with symptomatic Type 1 SMA and the SUNFISH study in children and young adults with Type 2 or 3 SMA.
- Evrysdi is commercialized in the U.S. by Genentech, a Roche Holdings AG member RHHBY.
- Roche leads the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.
- Price Action: PTCT shares closed 2.3% lower at $48.06 on Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
